Meetings and events

17

Apr, 2019

Global Health Festival, Padova, 5th-7th April

 

On April 5th-7th Padova (Italy) hosted the Global Health Festival. The aim of the festival was to investigate scientific progress and explore technological advances and policies that let the right to health to be increasingly universal and inclusive, in every corner of the world.

READ MORE

4

Apr, 2019

SMILE Clinical Trial: 100th Patient Enrolled

Tags: , ,

The Penta-sponsored clinical trial SMILE has achieved a significant milestone by recruiting its 100th patient yesterday. The patient was enrolled at the Perinatal HIV Research Unit (PHRU) in Soweto, South Africa.  This is a wonderful result achieved through hard work and cooperation among the sites, the CTUs and the sponsor.

READ MORE

1

Apr, 2019

GARDP and Penta partner to accelerate the development of children’s antibiotics to tackle AMR

 

Geneva / Padova, Monday 4 March 2019 – The Global Antibiotic Research & Development Partnership (GARDP) and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines. Globally, more than three million childhood deaths result from infectious diseases, such as pneumonia and sepsis (1). Children are also particularly affected by antimicrobial resistance […]

READ MORE

1

Apr, 2019

Launch of VALUE-Dx in Madrid marked with press release

 

The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. Coordinated by the University of Antwerp, the ambition of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded by the European Commission (IMI), the Wellcome Trust and private companies over a 4 year period.

READ MORE

1

Apr, 2019

University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics

Tags: ,

Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019 The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies. VALUE-Dx is co-funded […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities